Drug Profile
Research programme: orexin receptor antagonists - Johnson & Johnson
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Small molecules
- Mechanism of Action Orexin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Sleep disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sleep-disorders in USA (SC, Injection)
- 17 Nov 2010 Preclinical trials in Sleep disorders in USA (SC)
- 17 Nov 2010 Preclinical pharmacodynamics data in Sleep disorders presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010) ,